Orthobiologics market to reach $4,561m in 2018, a new study predicts

Monday 10 March 2014, Amsterdam

A new report forecasts the world market for orthobiologics will reach $4,561m in 2018. That revenue prediction and others appear in Ortho and Osteobiologics: World Industry and Market Analysis 2014-2024, published in January 2014.

Orthobiologics constitute products using biology or biochemistry to treat musculoskeletal disorders. Sales of those drugs and other reconstructive therapies rise.

The new report forecasts the world orthobiologics market will expand in revenues from 2014 to 2024. Orthobiologic agents emerge on to the orthopaedic drugs and medical devices market, and those biotechnologies have achieved commercial success. The new report finds the strength of orthobiologics is their ability to treat impaired healing. Sales growth of their market will be driven by a rise in the prevalence of osteoporosis and diabetes worldwide.

Jonathan Weymer, a pharmaceutical industry analyst, said: “Orthobiology forms an industry and market with immense potential. The number of people with osteoporosis and diabetes worldwide will increase over the next ten years, owing to ageing populations and changing lifestyles. These patients do not heal efficiently and surgeons have difficulty in achieving post-operative bone fusion and healing. Orthopaedic biomaterials offer a solution to this issue, and we expect product demand to increase rapidly in the coming 10 years.

“On the other side of orthobiologics, our analysis shows a demand for biologic treatments to prevent osteoporotic fractures. Ageing demographics will continue to stimulate demands for osteoporosis treatments that are easy to adhere to and enhance bone density. Our study notes that Amgen is set to dominate this market over the next ten years with its strong late- stage R&D pipeline and expanding Prolia sales.

“Our research shows market access and reimbursement will be a challenge during the forecast period 2014 to 2024. However, those difficulties will be overcome by clinical and economic evidence favouring orthobiologic treatments. So their future looks promising.”

The new report shows revenue forecasts to 2024 at overall world market, submarket, product and national level. It forecasts sales of these world-level submarkets:

• Machined bone allografts
• Demineralised bone matrices
• Recombinant growth factors
• Bone substitutes
• Stem-cell therapies
• Allograft implants
• Biological osteoporosis treatments.

The investigation also predicts revenues of leading products, including INFUSE, Prolia, Forteo and Preotact. Research, data and analyses cover activities of Medtronic, Eli Lilly, DePuy Synthes, Amgen, Stryker, Biomet, Wright Medical and other companies.

That study discusses R&D and commercial news, shows research interviews and predicts revenues to 2024 in leading regional and national markets. The work analyses the United States (US), the European Union (Germany, France, the UK, Spain, and Italy – EU5), Japan, the BRIC nations (Brazil, Russia, India, and China), and the rest of the world (as a group). The new analysis includes qualitative discussions and projections, research and development (R&D), and interviews with authorities on treating bone disorders.

Ortho and Osteobiologics: World Industry and Market Analysis 2014-2024 adds to the range of analytical reports on industries and markets in healthcare, studies covering pharmaceuticals, medical devices and diagnostics.